Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × ALK+ Advanced NSCLC × alectinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 16 Neoplasms 3 Urinary Bladder Neoplasms 1 Solid Tumors 1 Multiple Endocrine Neoplasia Type 2a 1 Lung Neoplasms 1 Lung Diseases 1 Central Nervous System Neoplasms 1 Biliary Tract Neoplasms 1 Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer 1 ALK-positive NSCLC 1 ALK+ Advanced NSCLC 1

Interventions

brigatinib 1 alectinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03596866 2025-09-12

ALTA-3

Takeda

Phase 3 Completed

248 enrolled 20 charts

ALK+ Advanced NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡